2016 Press Releases| Newsroom | Medtronic

2016 Press Releases


201620152014201320122011
Search News Releases
 
DateTitle  
05/25/16The Nederlandse Obesitas Kliniek and Medtronic Join Forces in the Battle Against Morbid Obesity
DUBLIN and EINDHOVEN / ZEIST, THE NETHERLANDS - May 25, 2016 - The Nederlandse Obesitas Kliniek ('Dutch Obesity Clinic', NOK) and Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, today announced that Medtronic has signed an agreement to enter into a strategic alliance, via a majority ownership position in NOK, with the goal of enhancing NOK's ability to offer integrated, value-based healthcare solutions for the treatment of morbid obesity to more patients... 
 Printer Friendly Version
05/25/16Medtronic and Qualcomm Collaborate to Aim to Improve Care and Health Outcomes for People with Type 2 Diabetes
Joint Development of Future Generation Continuous Glucose Monitoring (CGM) Systems Aims to Provide Actionable Insights to Help Deliver Integrated Diabetes Care DUBLIN and SAN DIEGO - May 25, 2016 - Medtronic plc (NYSE:MDT) and Qualcomm Incorporated (NASDAQ:QCOM) through its wholly-owned subsidiary, Qualcomm Life, Inc., today announced a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for peopl... 
 Printer Friendly Version
05/19/16Medtronic Announces U.S. Launch of Spine Essentials Demonstrating Its Commitment to Create Value in Healthcare
New Platform Increases Efficiencies and Reduces Costs Associated with Common Spinal Surgery DUBLIN and DALLAS - May 19, 2016 - Medtronic plc (NYSE: MDT) announced the U.S. launch of Spine Essentials(TM), a new platform of spinal implants and instruments designed to make the most common cervical spine fusion procedures more efficient and help hospital systems manage costs, while maintaining quality. The goal of Spine Essentials is to help surgeons and their staffs streamline the most common spin... 
Download PDFPrinter Friendly Version
05/18/16Medtronic to Expand Minimally Invasive Therapy Portfolio with Acquisition of Gynecology Business from Smith & Nephew
DUBLIN - May 18, 2016 - Medtronic plc (NYSE: MDT) today announced it has signed a definitive agreement to acquire Smith & Nephew's (NYSE: SNN; LSE: SN) gynecology (GYN) business for approximately $350 million. This agreement reinforces Medtronic's dedication to expanding the use of less invasive treatments and demonstrates a commitment to improving options for women with abnormal uterine bleeding (AUB). The addition of the GYN portfolio will expand and strengthen Medtronic's minimally invasive s... 
 Printer Friendly Version
05/17/16Medtronic EVP & MITG President Bryan Hanson to Speak at Jefferies Healthcare Conference
DUBLIN - May 17, 2016 -Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that the company will participate in the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016, in New York City. Bryan C. Hanson, executive vice president and president of Medtronic's Minimally Invasive Therapies Group (MITG), will answer questions about the company beginning at 11:00 a.m. Eastern Daylight Time. A live audio webcast of the presentation will... 
 Printer Friendly Version
05/17/16Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference
DUBLIN - May 17, 2016 -Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that it will participate in the 37th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 9:20 a.m. Pacific Daylight Time. A live audio webcast of the presentation will be available on June 7, 2016... 
 Printer Friendly Version
05/15/16Medtronic Statement on the Passing of Dr. Glen Nelson
MINNEAPOLIS - May 15, 2016 - Medtronic plc (NYSE:MDT) today issued the following statement regarding the passing of Dr. Glen Nelson: The 85,000 employees of Medtronic around the world are deeply saddened to learn of the passing of Dr. Glen Nelson.  Dr. Nelson served as the vice chairman of Medtronic from 1988 to 2002, and it is during this period that Medtronic rose to become the world's leading medical technology company - vastly expanding its medical technology portfolio and global prese... 
 Printer Friendly Version
05/11/16Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2016
DUBLIN - May 11, 2016 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the fourth quarter and fiscal year 2016, on Tuesday, May 31, 2016. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's fourth quarter and fiscal year 2016, which ended on Friday, April 29, 2016. Medtronic will host a webcas... 
Download PDFPrinter Friendly Version
05/11/16Medtronic and the Vikings to Unveil "The Horn" Monument on Medtronic Plaza Outside U.S. Bank Stadium
New 38-Ton Artistic Landmark Represents the Spirit of Progress and Partnership That Together Lead Our Community to a Better Future MINNEAPOLIS - May 11, 2016 - Medtronic plc (NYSE: MDT) and the Minnesota Vikings today announced Medtronic's contribution of a new contemporary art sculpture on Medtronic Plaza, just outside the Vikings' new home at U.S. Bank Stadium. Funded privately by Medtronic and designed by Minneapolis design firm Alliiance, the monument is titled "The Horn." The Ho... 
Download PDFPrinter Friendly Version
05/10/16Medtronic Announces 2016 Institutional Investor and Analyst Meeting and Webcast
DUBLIN - May 10, 2016 - Medtronic plc (NYSE:MDT) announced today that the company will host its biennial Institutional Investor and Analyst Meeting on Monday, June 6, 2016, in New York City from 8:00 a.m. to approximately 3:15 p.m. Eastern Daylight Time. The meeting will include remarks from the Medtronic executive management team on the company's plans for delivering consistent and reliable revenue growth, strong operating and financial leverage, significant accessible free cash flow, and strat... 
Download PDFPrinter Friendly Version
05/06/16Medtronic Unveils Data Showing Feasibility of New Approach to ICD Therapy
Studies Presented at Heart Rhythm 2016 Provide Encouraging Results for ICD Lead Placement Under Ribs, Outside Heart and Veins DUBLIN and SAN FRANCISCO - May 6, 2016 - Medtronic plc (NYSE:MDT) today announced the results of several studies evaluating a novel approach to implantable cardioverter defibrillator (ICD) therapy at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco. The Medtronic EV-ICD System, which currently is in development and not ava... 
Download PDFPrinter Friendly Version
05/05/16New Data Further Support Medtronic Leadership in Leadless Pacing at Heart Rhythm 2016
Data Add to Body of Evidence Supporting World's Smallest Pacemaker            Micra TPS is First Leadless Pacemaker to Receive FDA Approval DUBLIN and SAN FRANCISCO - May 5, 2016 - Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco. The Micra TPS is less than one-tenth the s... 
Download PDFPrinter Friendly Version
05/04/16Medtronic Welcomes Karen L. Parkhill as Its New Chief Financial Officer
Gary Ellis to Remain on Medtronic Executive Committee Until Retirement in Fiscal Year 2017 DUBLIN - May 4, 2016 - Medtronic plc (NYSE: MDT) announced today the appointment of Karen L. Parkhill as executive vice president and chief financial officer (CFO), effective June 20, 2016. Parkhill will succeed Gary L. Ellis in the CFO role and will report to Medtronic CEO Omar Ishrak. Today's announcement concludes an external search process conducted by the company to ensure a seamless succession ... 
Download PDFPrinter Friendly Version
05/03/16Late-Breaking Study Provides Evidence to Support Beneficial Seven-Year Clinical Outcomes and Patient Satisfaction for 2-Level Prestige LP(TM) Cervical Disc Patients
Study Represents Longest Patient Follow-Up Data for U.S. 2-Level Cervical Disc Patients DUBLIN and CHICAGO - May 3, 2016 - Medtronic plc (NYSE: MDT) today announced results of seven-year follow-up data demonstrating favorable clinical outcomes and patient satisfaction for the 2-level Prestige LP(TM) Cervical Disc compared to 2-level anterior cervical discectomy and fusion (ACDF). The Prestige LP Disc - currently indicated for single-level cervical disc disease causing nerve or spinal cord compr... 
Download PDFPrinter Friendly Version
05/02/16Medtronic Expands MRI-Compatible Portfolio with FDA Clearance of StrataMR(TM) Shunt System
Patients with Hydrocephalus and CSF Disorders Have Greater Access to Full Body MRI Scans with StrataMR DUBLIN - May 2, 2016 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) clearance of StrataMR(TM) valves and shunts, an addition to Medtronic's family of Strata® Adjustable Valve Systems used in the treatment of patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. The StrataMR system is intended to maintain its performance level setting durin... 
Download PDFPrinter Friendly Version
05/02/16Medtronic Receives FDA Approval for New Single-Chamber ICDs That Detect Atrial Fibrillation
Visia AF MRI(TM) SureScan® and Visia AF(TM)ICDs Treat Dangerous Heart Rhythms and Enable Physicians to Identify Patients at Increased Risk for Stroke and Heart Failure Due to AF DUBLIN - May 2, 2016 - Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Visia AF MRI(TM) SureScan® and Visia AF(TM) single-chamber implantable cardioverter defibrillators (ICDs). The Visia AF devices can detect previously undiagnosed and/or asymptomatic a... 
Download PDFPrinter Friendly Version
04/28/16Medtronic VenaSeal Closure System Demonstrates Long-Term Durability and Improved Quality of Life in Patients with Venous Reflux Disease
Medtronic Unveils Data for VenaSeal Closure System at Charing Cross and the International Vein Congress DUBLIN - April 28, 2016 - This week at the 2016 Charing Cross Symposium in London and the International Vein Congress in Miami, Medtronic plc (NYSE: MDT) unveiled clinical data for the VenaSeal(TM) closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease. The new data presented included two-year outcomes from the VeClose... 
Download PDFPrinter Friendly Version
04/27/16Medtronic Demonstrates Commitment to EVAR in Comparison Study of ENGAGE Global Registry and Landmark EVAR 1 Trial
Clinical Integrity on Display through Longest Term Data of 1,200 Endurant AAA Stent Graft Patients DUBLIN AND LONDON - April 27, 2016 - Medtronic plc (NYSE:MDT) today reported on the ENGAGE global registry of experiences with the Endurant® AAA stent graft system from Medtronic with a reference to the landmark EVAR 1 Trial. ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair (EVAR) with more than 1,200 patients at 79 sites across six c... 
Download PDFPrinter Friendly Version
04/26/16Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases
New Rigorous Analyses Presented at Charing Cross Reinforce Efficacy in Females, Chronic Total Occlusions and Patients with Diabetes; Data Details Unique, Sustained Benefit with IN.PACT Admiral DCB DUBLIN and LONDON - April 26, 2016 - Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACTTM AdmiralTM drug-coated balloon (DCB) with several new presentations that showed durable and consistent clinical outcomes in the most challenging patients with peri... 
Download PDFPrinter Friendly Version
04/21/16Medtronic Launches New Endoscopic Ablation Catheter for Barrett's Esophagus
BarrxTM 360 Express RFA Balloon Catheter's Adjustable Custom Fit Provides Targeted Precision Therapy - Allowing Physician Ease and Efficiency DUBLIN - April 21, 2016 - Medtronic (NYSE: MDT) today announced the launch of the new BarrxTM 360 Express radiofrequency ablation (RFA) balloon catheter, which can help in the treatment of Barrett's esophagus. The Barrx 360 Express catheter, with its self-adjusting circumferential RFA catheter, lets gastroenterologists and surgeons provide RFA treatment ... 
 Printer Friendly Version
04/20/16Real-World Study Shows 72 Percent of Atrial Fibrillation Would Have Gone Undiagnosed in Stroke Patients if Cardiac Monitoring Had Been Limited to 30 Days
Findings Demonstrate Detection of Atrial Fibrillation in Cryptogenic Stroke Patients with Medtronic Insertable Cardiac Monitor DUBLIN and VANCOUVER - APRIL 20, 2016 - Medtronic plc (NSYE: MDT) today announced one-year results from a real-world study of patients who had a cryptogenic stroke, or stroke of unknown cause. The study found that the Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) detected atrial fibrillation (AF) at a greater rate than previously reported in a randomized controlled c... 
Download PDFPrinter Friendly Version
04/20/16Medtronic Announces Worldwide Voluntary Recall for Battery Pack in Covidien Oridion Labeled Capnostream(TM)20 and Capnostream(TM)20p Patient Monitors
DUBLIN - April 20, 2016 - Medtronic is notifying customers worldwide of a voluntary recall for the battery pack used in its Covidien Oridion labeled Capnostream(TM)20 and Capnostream(TM)20p Patient Monitors. This voluntary recall is being conducted due to a battery manufacturing defect that may increase the risk of thermal damage in the battery pack. The scope of this recall includes battery pack model numbers 016400 and 010520. These packs were manufactured by a contract manufacturer between Ap... 
Download PDFPrinter Friendly Version
04/18/16Material in Medtronic Leads Inducted into Space Technology Hall of Fame®
Medtronic Applied NASA Technology into Its Cardiac Devices DUBLIN and COLORADO SPRINGS, COLO. - April 18, 2016 - The Space Foundation has inducted NASA Langley Research Center-Soluble Imide (LaRC-SI) - used in Medtronic plc (NYSE: MDT) leads connected to implantable cardiac devices - into the Space Technology Hall of Fame®. The ceremony was held during the Space Foundation's 32nd Space Symposium in Colorado Springs, Colo. LaRC-SI is an insulation material developed by researchers at the NASA (... 
Download PDFPrinter Friendly Version
04/14/16Medtronic Announces the Pricing Terms of Its Cash Tender Offer of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - April 14, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced the pricing terms of the previously-announced cash tender offer by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for up to $3 billion combined aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicable settleme... 
Download PDFPrinter Friendly Version
04/14/16Medtronic Announces the Early Results and Upsizing of Its Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - April 14, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced that, pursuant to the previously-announced cash tender offer by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors") for the Notes identified in the table below (the "Notes"), approximately $5.8 billion in aggregate principal amount of Notes were vali... 
Download PDFPrinter Friendly Version
04/13/16New Data Shows Benefits of Medtronic Insulin Pumps for People with Type 2 Diabetes
Study Shows Insulin Pumps Safely Provided Significant, Sustainable and Reproducible Improvements in Glucose Control in Comparison to Multiple Daily Injections DUBLIN - April 13, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of insulin pumps for people with insulin-requiring type 2 diabetes.  ... 
Download PDFPrinter Friendly Version
04/10/16Medtronic Responds to Star Tribune Article Regarding INFUSE Bone Graft
MINNEAPOLIS - April 10, 2016 - This weekend, an article was published in the Minneapolis Star Tribune that criticized Medtronic's handling of data collected during a retrospective chart review (RCR) of INFUSE Bone Graft between 2006-2008. The article makes insinuations that are false, and fails to include important information regarding the RCR and Medtronic's actions. Medtronic provided the Star Tribune an extensive account of what transpired around the RCR, both in person and in writing, whic... 
 Printer Friendly Version
04/06/16FDA Approves World's Smallest Pacemaker for U.S. Patients
The Medtronic Micra® TPS is the First Transcatheter Pacemaker Approved in the U.S. Gives Patients Access to the Most Advanced Pacing Technology at One-Tenth the Size of Traditional Devices DUBLIN - April 6, 2016 - Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is the first FDA-approved product with miniaturized pacing technology. It... 
Download PDFPrinter Friendly Version
04/06/16Medtronic Statement on U.S. Department of Treasury's Recent Temporary and Proposed Regulations
DUBLIN - April 6, 2016 - Medtronic plc (NYSE: MDT) has conducted a preliminary review of the United States Department of Treasury Temporary and Proposed Regulations issued on April 4, 2016, which are designed to address certain concerns around transactions referred to by Treasury as "tax inversions" and "earnings stripping." Medtronic has concluded that the Temporary and Proposed Regulations do not have a material financial impact on any transaction undertaken by the company.... 
Download PDFPrinter Friendly Version
04/04/16First-Ever Medtronic Harmony(TM) Transcatheter Pulmonary Valve Data Shows Positive Procedural Success In Early Feasibility Study
Encouraging Early Outcomes from Rigorously Designed Study Set the Stage for IDE DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced first-ever clinical data on the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study, demonstrating positive initial outcomes at six-months in patients with an indication for pulmonary valve restoration. The initial results were presented during the 65th Annual Scientific Session of the American College of Cardi... 
Download PDFPrinter Friendly Version
04/04/16Medtronic Arctic Front® Cryoballoon Catheters Meet Non-Inferiority Goal in Head-to-Head Trial Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine
Cryoballoon Comparable in Safety and Effectiveness as Current Standard of Care Ablation Technology DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced positive results from the landmark FIRE AND ICE clinical trial, which demonstrated comparable safety and effectiveness for its Arctic Front® Cryoballoon Catheter Family compared to the ThermoCool® line of radiofrequency (RF) ablation catheters for the treatment of symptomatic paroxysmal atrial fibrillation (AF). The stud... 
Download PDFPrinter Friendly Version
04/03/16Medtronic CoreValve® System Maintains Survival Advantages Over Surgery in High Risk Aortic Stenosis Patients at Three Years
New Data at ACC.16 First to Show Superior, Longer-Term Outcomes for Self-Expanding TAVR vs. SAVR at Three Years  Results Published Simultaneously in the Journal of American College of Cardiology (JACC) DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) today announced new data from the High Risk Study of the CoreValve U.S. Pivotal Trial that show superior clinical outcomes for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to surgical aortic valve r... 
Download PDFPrinter Friendly Version
04/03/16Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent Trial
RevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16  DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent (DFS). These new data showed rapid vessel healing without inflammation in Optical Coherence Tomography (OCT) data of the complete one-month follow-up patient cohort. The re... 
 Printer Friendly Version
04/02/16Medtronic CoreValve® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
New Sub-study at ACC.16 from the CoreValve U.S. High Risk Trial Shows Exceptional Valve Performance for the Self-Expanding Transcatheter Heart Valve at Two Years DUBLIN and CHICAGO - April 2, 2016 - Medtronic plc (NYSE: MDT) today unveiled new clinical data on the self-expanding CoreValve® System from the High Risk Study of the CoreValve U.S. Pivotal Trial, showing superior outcomes in survival for transcatheter aortic valve replacement (TAVR) compared to surgery at two years for the subgroup of... 
 Printer Friendly Version
03/31/16Medtronic Announces Cash Tender Offer for Up to $2.75 Billion Aggregate Purchase Price of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - March 31, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer (the "Tender Offer") by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for up to $2.75 billion combined aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicabl... 
Download PDFPrinter Friendly Version
03/31/16First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients
DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. The first patients were enrolled at PinnacleHealth CardioVascular Institute in Harrisburg, PA. The heart team led by Mubashir Mumtaz, M.D., F.A.C.S., F.A.C.C. ch... 
Download PDFPrinter Friendly Version
03/31/16Medtronic Receives Expanded Indication From FDA for Pillcam(TM) Colon 2 Capsule
Potentially Reaching More Patients at Risk for Colon Cancer  DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) cleared PillCam(TM) COLON 2 capsule for an expanded indication for use. The PillCam(TM) COLON 2 capsule is the only non-invasive diagnostic test that directly visualizes the colon for the evaluation of polyps in patients who are at major risks for colonoscopy or moderate sedation. The PillCam(TM) capsule- a vitamin-sized... 
 Printer Friendly Version
03/30/16Medtronic Launches Percutaneous Tibial Neuromodulation Delivered by the NURO System for the Treatment of Overactive Bladder (OAB)
New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive bladder (OAB) with symptoms of urinary urgency, urinary frequency, and urge incontinence. PTNM, a minimally invasive, periodic, office-based proced... 
Download PDFPrinter Friendly Version
03/29/16Medtronic Foundation Seeks Runners Benefitting from Medical Technology for 2016 "Global Heroes" Team
Applications now open: www.medtronic.com/globalheroes Selected runners receive entry and travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2016 Cancer, Stroke, Obesity added to list of eligible medical conditions DUBLIN - March 29, 2016 - Applications are now open for the 2016 Global Heroes running team. Every October since 2006, the Medtronic Foundation and Twin Cities In Motion have brought people from around the world to Minnesota to be part of a unique collect... 
 Printer Friendly Version
03/21/16Medtronic EVP & President, Hooman Hakami to Speak at Deutsche Bank Medtech Boot Camp Healthcare Conference
DUBLIN - Mar 21, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the Deutsche Bank MedTech Boot Camp on Monday, March 21, 2016, in Boston, Massachusetts. Homan Hakami, executive vice president and president of Medtronic's Diabetes Group, will make a presentation on the company beginning at 2:05 p.m. EDT (1:05 p.m. CDT). A live audio webcast of the presentation will be available on March 21, 2016, by clickin... 
Download PDFPrinter Friendly Version
03/17/16Medtronic Proposes Proxy Access
DUBLIN - March 17, 2016 - Medtronic plc (NYSE: MDT) will put forth a board proposal supporting the adoption of proxy access in its 2016 proxy statement.  Proxy access would allow long-term shareholders the ability to nominate their own director candidates for election to the Board of Directors and have such director candidates included on the company's proxy card, along with any candidates nominated by the Board of Directors. Pending shareholder approval, the board proposal to amend the company... 
Download PDFPrinter Friendly Version
03/10/16First European Patients Enroll in Medtronic International Lung Cancer Study
NAVIGATE Study Assesses Impact of Minimally Invasive Technology to Aid in Early Diagnosis and Treatment of Lung Cancer DUBLIN - March 10, 2016 - Committed to technologies that assist in the goal of reducing lung cancer morbidity worldwide, Medtronic (NYSE: MDT) today announced European enrollment in the NAVIGATE clinical trial. This 2,500-patient international study will assess the long-term impact of its superDimension(TM) navigation system as an aid in early detection of lung cancer and subse... 
Download PDFPrinter Friendly Version
03/07/16Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference
DUBLIN - Mar 7, 2016 - Medtronic plc  (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016, in Miami Beach, Florida. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation on the company beginning at 9:30 a.m. EDT (8:30 a.m. CDT). A live audio webcast of the presentation will be available on March 17, 2016, by click... 
Download PDFPrinter Friendly Version
03/07/16Medtronic Enrolls First Patients in Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) R System in 'Real-World' Setting
FORWARD Clinical Study Designed to Confirm the Exceptional Results Achieved in the Evolut R CE Study DUBLIN - March 7, 2016 - Medtronic plc (NYSE: MDT) today announced the first patients enrolled in the Evolut R FORWARD Clinical Study, a global, multi-center, single-arm, prospective study of up to 1,000 patients, to evaluate performance outcomes using the CoreValve(TM) Evolut(TM) R System in everyday clinical practice. A next-generation, recapturable and repositionable transcatheter aortic val... 
Download PDFPrinter Friendly Version
03/04/16Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference
DUBLIN - Mar 4, 2016 - Medtronic plc  (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the 36th Annual Cowen & Company Healthcare Conference on Tuesday, March 8, 2016, in Boston, Massachusetts. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a formal presentation on the company beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be av... 
Download PDFPrinter Friendly Version
03/03/16Medtronic the First to Offer Complete Portfolio of Full-Body MR Conditional Neurostimulation Systems for Chronic Pain
FDA Approval of Medtronic Specify® SureScan® MRI Surgical Leads Rounds Out Exclusive Portfolio Designed for Access to Full-Body MRI[*] DUBLIN - March 3, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Specify® SureScan® MRI surgical leads, which are indicated for use as part of Medtronic implanted neurostimulation (also known as spinal cord stimulation, or SCS) systems for chronic pain. In 2013, Medtronic introduced the only implantable neuro... 
Download PDFPrinter Friendly Version
03/01/16Medtronic Reports Third Quarter Financial Results
Revenue of $6.9 Billion Grew 6% on a Comparable, Constant Currency Basis; 61% as Reported  NON-GAAP Diluted EPS of $1.06; GAAP Diluted EPS of $0.77 Adjusted Free Cash Flow of $1.8 Billion; GAAP Cash Flow from Operations of $1.8 Billion DUBLIN - March 1, 2016 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2016, which ended January 29, 2016. Unless otherwise noted, all revenue growth rates in this press release are stated on a compara... 
Download PDFPrinter Friendly Version
02/22/16Medtronic Receives FDA Approval for Expanded Indication Trial in Low-Risk Aortic Stenosis Patients
DUBLIN - February 22, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial. Enrollme... 
Download PDFPrinter Friendly Version
02/22/16Medtronic Receives CE Mark for Full Line of Cardiac Resynchronization Therapy-Defibrillators Compatible with MRI Scans
Now Offering Both 1.5 and 3 Tesla Indications for MR-Conditional ICMs, Pacemakers, ICDs and CRT-Ds DUBLIN - February 22, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for the first and only cardiac resynchronization therapy defibrillators (CRT-Ds) approved for 3 Tesla (T) magnetic resonance imaging (MRI) scans, providing CRT-D patients with access to the most advanced imaging diagnostic procedures available. This full line of CRT-Ds - also... 
Download PDFPrinter Friendly Version
02/19/16Medtronic Named Among the World's Most Admired Companies by Fortune Magazine
Ranked Second Within Medical Products and Equipment Category DUBLIN - February 19, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, has been designated as one of the World's Most Admired Companies by FORTUNE Magazine. Within the Medical Products and Equipment industry category, Medtronic ranked second globally. This 2016 listing was released today, and is considered one of the leading measures of corporate reputation among the world's largest com... 
Download PDFPrinter Friendly Version
02/19/16Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2016
DUBLIN - February 19, 2016 - Medtronic plc (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2016 on Tuesday, March 1, 2016. A news release will be issued at approximately 5:45 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for the third fiscal quarter, which ended January 29, 2016. Medtronic will host a webcast at 7:00 a.m. Central Standar... 
Download PDFPrinter Friendly Version
02/19/16Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2016
DUBLIN - February 19, 2016  - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2016 fourth quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2015.  Medtronic has increased its annual dividend payment for the past 38 consecutive years, and is a constituent of the S&P 500 Dividend Aristocrats index.  The divide... 
Download PDFPrinter Friendly Version
02/18/16Meta-Analysis Shows Medtronic's Solitaire(TM) Stent Retriever Device Improves Functional Outcomes for Acute Ischemic Stroke Patients; Reduced Mortality in Patients 80+
SEER Pooled, Patient-Level Analysis of SWIFT PRIME, EXTEND-IA, ESCAPE and REVASCAT Shows Safety and Efficacy of Solitaire Device DUBLIN - February 18, 2016 - A meta-analysis published online today in Stroke and presented at the International Stroke Conference (ISC) in Los Angeles, Calif., found that the addition of Medtronic plc's (NYSE: MDT) Solitaire(TM) stent retriever to current pharmaceutical treatment (IV-tPA) significantly improves functional outcomes in patients suffering stroke. Safety... 
Download PDFPrinter Friendly Version
02/17/16FDA Approves Medtronic Deep Brain Stimulation for People with Parkinson's Disease with Recent Onset of Motor Complications
Approval Expands Population of Individuals Who May Benefit From the Proven Therapy DUBLIN - February 17, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Medtronic Deep Brain Stimulation (DBS) Therapy for use in people with Parkinson's disease of at least four years duration and with recent onset of motor complications, or motor complications of longer-standing duration that are not adequately controlled with medication. In 2002, the FDA initi... 
Download PDFPrinter Friendly Version
02/12/16NICE Recommends Medtronic Integrated Sensor-Augmented Insulin Pump As the Only Therapy System to Manage Glucose Levels in Type 1 Diabetes
The NICE guidance reviewed two sensor-augmented insulin pump therapy systems and recommends the MiniMed® Paradigm Veo(TM) system for managing glucose levels in people with Type 1 diabetes.1 The MiniMed Paradigm Veo and the MiniMed 640G sensor-augmented insulin pump therapy systems can help to protect against severe hypoglycemia in people with Type 1 diabetes by continuously monitoring glucose levels. NICE concluded that the adoption of Medtronic technology has the potential to save a UK health s... 
Download PDFPrinter Friendly Version
02/09/16First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic Aneurysm Study
Sanford Health in Collaboration with Medtronic Leads Global Efforts to Address Challenging Vascular Condition DUBLIN and SIOUX FALLS, S.D. - February 9, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions and Sanford Health, one of the nation's largest health care systems, today announced the first patient enrolled in a clinical study using the Medtronic Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm.... 
Download PDFPrinter Friendly Version
02/05/16Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
iPro2 Professional CGM Provides Information to Help Physicians Optimize Care for Their Patients Regardless of Their Diabetes Therapy MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication o... 
Download PDFPrinter Friendly Version
02/05/16Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
Amplia MRI(TM) and Compia MRI(TM) CRT-Ds, Approved for Patients with Heart Failure, Can Safely Undergo Full Body MRI Scans DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure. The Medtronic Amplia MRI(TM) Quad CRT-D SureScan® and Compia MRI(TM) Quad CRT-... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications
New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left mai... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds Life-Extending Dialysis Portfolio to Recently Formed Renal Care Solutions Business with Acquisition of Bellco
DUBLIN - February 1, 2016 - Furthering its commitment to improve outcomes, expand therapy access, and optimize costs and efficiencies in end stage renal disease (ESRD), Medtronic plc (NYSE: MDT) today announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions.  Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business.  Bellco has created therapies and ... 
Download PDFPrinter Friendly Version
01/30/16Medtronic Presents Innovation Village – The First-Of-Its-Kind Initiative – At The 2nd Medical Device Summit in New Delhi
NEW DELHI – 30 January 2016 – For the second year in a row, Medtronic hosted the Medical Device Summit in New Delhi on 30th January 2016, bringing together leading national and international healthcare practitioners, research scientists, and business leaders. The theme of this year’s Summit was “Technological Innovation,” and speakers shared their views and latest updates on innovation and clinical outcomes driving the evolution of the healthcare ecosystem. The Summit ad... 
Download PDFPrinter Friendly Version
01/29/16Medtronic to Present Data on Micra® Transcatheter Pacing System at Upcoming FDA Advisory Committee Meeting
DUBLIN - January 29, 2016 - Medtronic plc (NYSE: MDT) will present data on the world's smallest pacemaker, the Micra® Transcatheter Pacing System (TPS), at the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee on Feb. 18, 2016, in Gaithersburg, Maryland. According to the FDA, the committee will meet to discuss and make recommendations on clinical trial research, post-approval study design, and physician training requirements for le... 
Download PDFPrinter Friendly Version
01/13/16Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool(TM) RF Ablation System
Minimally-Invasive Procedure Brings Relief to Patients Suffering from Painful Spine Tumors DUBLIN - January 13, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the OsteoCool(TM) RF Ablation System.  For physicians who treat patients with painful spine metastases, the OsteoCool System is the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities - providing procedural flex... 
 Printer Friendly Version
01/11/16Medtronic Updates Capital Allocation Plans and Fiscal 2016 EPS Guidance
Executing Incremental $5 Billion Share Repurchase Tightening EPS Guidance Due to Benefit of U.S. R&D Tax Credit DUBLIN - Jan 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today updated its capital allocation plans for the approximately $9.3 billion resulting from the previously announced September 2015 internal reorganization as part of the company's integration of Covidien legal entities. Separately, the company today reiterated its re... 
Download PDFPrinter Friendly Version
01/11/16Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease
IN.PACT Admiral DEB with 40 Centimeter Catheter Enables Physicians to Maintain Arteriovenous (AV) Access in Patients Undergoing Hemodialysis DUBLIN - January 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced that the IN.PACT® Admiral® drug eluting balloon (DEB) (also known as the IN.PACT Admiral drug-coated balloon (DCB) in non-European markets) has received CE (Conformité Européene) Mark for arteriovenous (AV) access to help ma... 
Download PDFPrinter Friendly Version
01/11/16Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement
New Agreement Will Help Expand Access to Advanced Diabetes Therapies in China DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.  As part of the agreement, Medtronic will invest in a manufacturing facility for a next generation sensor augmented pump system with SmartGuard(TM) technology to help pro... 
Download PDFPrinter Friendly Version
X